StoxCipla vs Aurobindo Pharma: share price & financials comparison
NSE: CIPLA vs AUROPHARMA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cipla vs Aurobindo Pharma at a glance
Cipla (CIPLA) has a market capitalisation of ₹1,13,988 Cr, against ₹1,03,572 Cr for Aurobindo Pharma (AUROPHARMA). Over the past year Aurobindo Pharma has returned +61.9%, compared with -10.8% for Cipla. On valuation, Aurobindo Pharma trades at a lower P/E of 26.0 versus 39.3. Aurobindo Pharma earns a higher return on equity (10.1% vs 8.2%). Cipla comes out ahead on size and financial health. Aurobindo Pharma comes out ahead on valuation, profitability, growth, momentum and technicals. Across the scored metrics below, Cipla leads on 5 and Aurobindo Pharma on 13. On StoxGud's 10-point checklist, Cipla scores 6/10 and Aurobindo Pharma scores 9/10.
| Metric | Cipla | Aurobindo Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,13,988 Cr | ₹1,03,572 Cr |
| Revenue (latest FY) | ₹28,163 Cr | ₹33,653 Cr |
| Net profit (latest FY) | ₹3,879 Cr | ₹3,505 Cr |
| Valuation | ||
| P/E | 39.3 | 26.0 |
| P/B | 3.22 | 2.63 |
| Dividend yield | 1.13% | 0.22% |
| Profitability | ||
| Return on equity | 8.2% | 10.1% |
| Net profit margin | 10.3% | 10.8% |
| Operating margin | 17.0% | 20.5% |
| Growth | ||
| Revenue growth (YoY) | -2.4% | +23.9% |
| Net profit growth (YoY) | -35.1% | +32.7% |
| Revenue CAGR (multi-year) | +8.0% | +6.3% |
| Financial health | ||
| Debt to equity | 0.01 | 0.21 |
| Momentum | ||
| 1-month return | +6.3% | +7.0% |
| 1-year return | -10.8% | +61.9% |
| 3-year CAGR | +5.4% | +27.2% |
| 5-year CAGR | +9.1% | +21.8% |
| 10-year CAGR | +10.0% | +8.9% |
| Distance from 52W high | -8.4% | +0.0% |
| Technicals | ||
| RSI (14) | 82 | 67 |
| Price vs 200-day avg | +3.5% | +22.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cipla | Aurobindo Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 6/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cipla or Aurobindo Pharma?
Cipla has a market cap of ₹1,13,988 Cr and Aurobindo Pharma has a market cap of ₹1,03,572 Cr as of 06 Nov 2026.
Which has a lower P/E, Cipla or Aurobindo Pharma?
Aurobindo Pharma has the lower P/E: Cipla trades at 39.3 and Aurobindo Pharma at 26.0.
Which gave better returns in the last year, Cipla or Aurobindo Pharma?
Aurobindo Pharma did better: Cipla returned -10.8% and Aurobindo Pharma returned +61.9% over one year.
Is Cipla or Aurobindo Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Cipla scores 6/10 and Aurobindo Pharma scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.